Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis.
Elisa GiacominiMelania LeograndeValentina PerroneMargherita AndrettaMarcello BaccaAlessandro ChinellatoAndrea CiacciaMariarosaria CilloRenato LombardiDaniela ManciniRomina PagliaroMaurizio PastorelloCataldo ProcacciLuca Degli EspostiPublished in: Healthcare (Basel, Switzerland) (2023)
This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II and, III, were included). The index date was that of first prescription of HAE treatments within the inclusion period (01/2010-06/2021) or of the date of exemption. The number of HAE patients included was 148 (43.2% male, mean age 43.3 years). Gastrointestinal disorders affected 36.5% patients, hypertension affected 28.4%, hypercholesterolemia affected 11.5%, and depression affected 9.5%. The frequent gastrointestinal involvement was further confirmed by the use of antiemetics and systemic antihistamines that doubled after the index date. Among patients enrolled by treatment ( n = 125), n = 105 (84%) were receiving a treatment for acute attacks. This analysis provided insights into the characterization of patients with HAE and their management in Italian clinical practice, suggesting that an unmet therapeutic need could be present for such patients in terms of the clinical burden.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- healthcare
- peritoneal dialysis
- public health
- mental health
- type diabetes
- clinical practice
- risk assessment
- blood pressure
- depressive symptoms
- deep learning
- intensive care unit
- physical activity
- machine learning
- coronary artery disease
- patient reported outcomes
- liver failure
- angiotensin ii
- big data
- climate change
- acute respiratory distress syndrome
- sleep quality
- adverse drug